NAMS

18.3855.77%
MA

Mayur Amrat Somaiya

Chief Financial Officer

Mr. Mayur Amrat Somaiya, also known as Ian, is Director of ImmPACT Bio USA Inc. from August 2024. He is Chief Executive Officer of NewAmsterdam Pharma Company N.V. since October 2023 and joined the company in October 2023. He served as Chief Financial Officer and Chief Business Officer of Elucida Oncology, Inc. since November 2021. He joined Elucida Oncology in November 2021. He served as the Chief Financial Officer of TCR2 Therapeutics Inc. (formerly known as TCR2, Inc.) since December 2018. From 2015 to 2018, he was the Managing Director and Head of Biotechnology Research at BMO Capital Markets Equity Research. He was employed at the firm from January 13, 2016 till April 10, 2018. Mr. Somaiya covered the biotechnology sector within healthcare sector. Prior to this, he was a Managing Director and Equity Analyst at Nomura Securities Co. Ltd., Research Division from 2013 to 2015, Piper Jaffray Companies and Thomas Weisel Partners Group, Inc. He has experience in finance and healthcare as a highly regarded biotechnology research Analyst as well as operational experience. Prior to joining TCR2, he worked on Wall Street where he conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. Mr. Somaiya covered America’s biotechnology sector at the firm. Prior to that, he served as a Senior Research Analyst at Piper Jaffray Companies, Research Division since joining in 2010 and served as its Managing Director until 2009. Mr. Somaiya covered the biotechnology industry under the healthcare sector. He was also the lead Biotechnology Analyst at the firm and covered large and mid-to-small cap companies. Previously, Mr. Somaiya served as a Managing Director of Biotechnology, Research at Thomas Weisel Partners Group, Inc. He served as a Research Analyst at Morgan Stanley, Research Division from 2000 to 2003 with responsibilities for small-cap and mid-cap biotechnology companies. Mr. Somaiya worked with The Carson Group in its healthcare consulting practice prior to making his transition to the sell-side at Prudential Securities. During his career, Mr. Somaiya conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. He was recognized as the “Best on the Street” by the Wall Street Journal for his coverage on Biotechnology in 2006, 2007 and 2009. Mr. Somaiya received a Bachelor of Arts degree in Biology and Neuroscience from New York University.

Positions